Clinical Usefulness of Doxazosin in Patients with Type 2 Diabetes Complicated by Hypertension: Effects on Glucose and Lipid Metabolism

Abstract

This uncontrolled study investigated the effects of using the α₁-blocker doxazosin (2 mg or 4 mg daily for 3 months) to treat 21 hypertensive patients with type 2 diabetes, including eight obese individuals (body mass index [BMI] > 25.0 kg/m²). A significant reduction in systolic and diastolic blood pressure, beginning after 1 month of treatment, was seen. There was no significant change in BMI. Although there was no obvious improvement in glucose metabolism, doxazosin treatment noticeably reduced insulin resistance and significantly lowered triglyceride and free fatty acid levels. No significant changes were found in total cholesterol, high-or low-density lipoprotein-cholesterol, atherosclerotic index, or small or large subfractions of low-density lipoprotein-cholesterol. None of the patients showed any adverse effects. The beneficial effects of doxazosin on blood pressure and lipid and glucose metabolism shown in this study suggest that this drug is clinically useful as an anti-hypertensive agent for patients with diabetes.

Keywords

Doxazosin Type 2 diabetes Insulin resistance Lipid metabolism Low-density lipoprotein subfraction

References

Hypertension in Diabetes Study Group: Hypertension in Diabetes Study (HDS): II. Increased risk of cardiovascular complications in hypertensive type 2 diabetic patients. J Hypertens 1993; 11: 319–325

Katayama

: Management of hypertension in diabetic patients — an approach to therapeutic guidelines (in Japanese). Ther Res 1998; 19: 2953–2961

Reaven

: Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607

Giorda

Appendino

: Effects of doxazosin, a selective alpha 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. Metabolism 1993; 42: 1440–1442

Sato

Fukuzawa

Toyota

: Metabolic abnormalities and α-blockers (in Japanese). J Blood Press 1998; 5: 1123–1128

Miyashita

Shirai

: Abnormal lipid metabolism and α-blockers (in Japanese). J Blood Press 1998; 5: 1129–1133

Matthews

Hosker

Rudenski

Naylor

Treacher

Turner

: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419

Maruyama

Yanagisawa

Kanamuro

Teno

Iwamoto

: Serum leptin level as an indicator to predict the clinical efficacy of troglitazone in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 53: 161–164

McNamara

Campos

Ordovas

Peterson

Wilson

PWF

Schaefer

: Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis 1987; 7: 483–490

10.

Musliner

Krauss

: Lipoprotein subspecies and risk of coronary disease. Clin Chem 1988; 34: B78–B83

11.

Giordano

Matsuda

Sanders

Canessa

DeFronzo

: Effects of angiotensin-converting enzyme inhibitors, Ca²+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665–671

12.

Kageyama

Yamamoto

Mimura

Sakurai

Ishibashi

Aihara

: Doxazosin improves insulin sensitivity in hypertensive patients. Clin Ther 1993; 15: 829–837

13.

Tozawa

Iseki

Oshiro

Higashiuesato

Ikemiya

: Impact of multiple risk factor clustering on the elevation of blood pressure. Hypertens Res 2002; 25: 811–816

14.

Yamasaki

Shiba

Sekiya

Tsujino

Hakui

Kawamori

: Selective α1-adrenergic inhibition improves decrease glucose disposal in patients with essential hypertension. J Hum Hypertens 1994; 8: 555–558

15.

Shieh

Sheu

Shen

Fuh

Chen

Reaven

: Glucose, insulin, and lipid metabolism in doxazosin-treated patients with hypertension. Am J Hypertens 1992; 5: 827–831

16.

Huupponen

Lehtonen

Vahatalo

: Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. Eur J Clin Pharmacol 1992; 43: 365–368

17.

Ando

Ono

Shimozawa

Takahashi

Fujita

: Effects of doxazosin (Cardura®) on glucose tolerance and lipid metabolism (in Japanese). J Med Pharm Sci 1993; 29: 793–799

18.

Muto

: Usefulness of doxazosin in hypertensive diabetic patients (in Japanese). J New Rem Clin 1994; 43: 930–934

19.

Miura

: Usefulness of doxazosin mesylate in hypertensive patients with complications of diabetes and serum lipid abnormalities (in Japanese). Ther Res 1994; 15: 1221–1232

20.

Andersson

Lithell

: Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996; 9: 323–333

21.

Shionoiri

: Use of the α₁ blocker doxazosin in hypertensive patients with abnormal glucose tolerance; long-term antihypertensive results and effects on glucose and lipid metabolism -a multicenter prospective trial (in Japanese). J Med Pharm Sci 1994; 31: 485–494

22.

Kano

Kawashima

Aoki

Sobajima

: Effects of doxazosin in diabetic patients — a study of early-stage diabetic nephropathy and insulin sensitivity (in Japanese). J Med Pharm Sci 1995; 33: 453–457